Q2 2019 Y-mAbs Therapeutics, Inc Earnings Call Transcript
Greetings and welcome to the Y-mAbs Therapeutics Inc. second-quarter 2019 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Mr. Thomas Gad, Chairman and President of Y-mAbs. Thank you, Mr. Gad. You may begin.
Thank you, Terry. Hello, everyone, and thank you for dialing into our second-quarter earnings call. Today we will hear remarks from our Chief Executive Officer, Dr. Claus Moller, and our Chief Financial Officer, Bo Kruse.
Overall, we are very pleased with our second-quarter results. Our reported spending of $27.5 million year to date is really a direct result of our highly dedicated and productive team effort to prepare Y-mAbs to be ready to submit two BLAs in 2019.
We ended the quarter with $120 million in cash. And taking into consideration our potential approval timelines of Q3 2020 for naxitamab and omburtamab, and also
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |